Time-dependent population PK models of single-agent atezolizumab in patients with cancer

ConclusionThe overall impact of covariates on atezolizumab CL did not warrant any change in atezolizumab dosing recommendations. The results support the hypothesis that variation in atezolizumab CL over time is associated with patients ’ disease status, as shown with other checkpoint inhibitors.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research